SUBSCRIBE
SUBSCRIBE

TG Therapeutics, Inc.

NEWS
Pharm Country
TG Therapeutics, Inc. to Present at the 31st Annual J.P. Morgan Healthcare Conference
January 7, 2013
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. Announces FDA Clearance to Commence Clinical Trials of Its Novel, PI3K-Delta Specific Inhibitor, TGR-1202, Under Its Recently Filed U.S. Investigational New Drug (IND) Application
January 3, 2013
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference
December 11, 2012
 · 
1 min read
Drug Development
TG Therapeutics, Inc. Announces Poster Presentation Highlights for Ublituximab (TG-1101) and TGR-1202 From the 54th American Society of Hematology Meeting
December 10, 2012
 · 
1 min read
Drug Development
TG Therapeutics, Inc. Initiates a Phase I/II Clinical Trial of Its Novel Third-Generation Anti-CD20 Monoclonal Antibody, TG-1101 (Ublituximab), in Combination With Lenalidomide (Revlimid®) in Patients With B-Cell Lymphoid Malignancies
December 7, 2012
 · 
1 min read
Business
TG Therapeutics, Inc. Announces Exclusive Licensing Agreement With Ildong Pharmaceutical Co., Ltd. for Development and Commercialization of Ublituximab (TGTX-1101) in South Korea and Southeast Asia
November 15, 2012
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. Provides Update on NASDAQ Up-Listing Process
November 14, 2012
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. to Present at Lazard Capital Markets 9th Annual Healthcare Conference
November 13, 2012
 · 
1 min read
Business
TG Therapeutics, Inc. Announces Third Quarter 2012 Financial Results and Business Update
November 9, 2012
 · 
1 min read
Business
TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2012 Financial Results
November 7, 2012
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. to Participate in the Brean Capital 2012 Life Sciences Summit
November 6, 2012
 · 
1 min read
Drug Development
TG Therapeutics, Inc. Initiates a Phase I/II Clinical Trial of Its Novel Third-Generation Anti-CD20 Monoclonal Antibody, Ublituximab, in Patients With Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma
September 5, 2012
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. Announces Poster Presentation for Ublituximab (TGTX-1101) at the 7th International Workshop on Waldenstrom’s Macroglobulinemia
August 24, 2012
 · 
1 min read
Business
TG Therapeutics, Inc., Rhizen Pharmaceuticals S.A. Ink Deal Worth Up to $250 Million
August 16, 2012
 · 
5 min read
Pharm Country
TG Therapeutics, Inc. Announces Investigational New Drug (IND) for TGTX-1101, Receives Clearance by the FDA to Commence Clinical Trials in the U.S.
May 15, 2012
 · 
1 min read
Pharm Country
Manhattan Pharmaceuticals, Inc. Announces Name Change to TG Therapeutics, Inc. and Reverse Stock Split
April 27, 2012
 · 
3 min read
Load More
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
JOBS